BioSpace News Archive

OmicsEdge has proudly announced the presentation of their revolutionary new ancestry inference method at the European Society of Human Genetics meeting held in Glasgow, Scotland.

Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) (“Dermata” or the “Company”) today announced that following the Company’s receipt of FDA responses to its End of Phase 2 meeting package, the Company’s DMT310 Phase 3 clinical development program for the once-weekly topical treatment of patients with moderate-to-severe acne is on track to begin in the second half of 2023.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the publication of a new paper in Frontiers in Aging, a peer-reviewed journal focused on age-related scientific research.

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment.

Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage,

Dr. Brian Cornblatt will give the keynote address on the “HealthConf” Stage at Collision

Phantom Neuro, the pioneering neurotech startup, announced the successful demonstration of their technology in a porcine model.

SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health.

GRI Bio, Inc. today provided an update to the progress of its patent portfolio development.